Citius Oncology, Inc. (CTOR)
0.8516
+0.06
(+7.50%)
USD |
NASDAQ |
Sep 04, 15:11
Citius Oncology Total Liabilities (Quarterly) : 71.71M for June 30, 2026
Total Liabilities (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 71.71M |
| March 31, 2026 | 65.43M |
| December 31, 2025 | 51.56M |
| September 30, 2025 | 56.08M |
| June 30, 2025 | 59.31M |
| March 31, 2025 | 55.80M |
| December 31, 2024 | 49.19M |
| September 30, 2024 | 0.00 |
| June 30, 2024 | |
| March 31, 2024 | |
| December 31, 2023 | 2.046M |
| Date | Value |
|---|---|
| September 30, 2023 | 1.169M |
| June 30, 2023 | 0.4639M |
| March 31, 2023 | 0.0478M |
| December 31, 2022 | 0.0318M |
| September 30, 2022 | 0.2669M |
| June 30, 2022 | 0.2207M |
| March 31, 2022 | 0.1965M |
| January 31, 2022 | |
| October 31, 2021 | |
| July 31, 2021 | |
| April 30, 2021 | 0.0534M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| Citius Pharmaceuticals, Inc. | 66.35M |
| ACADIA Pharmaceuticals, Inc. | 436.29M |
| Alnylam Pharmaceuticals, Inc. | 4.205B |
| Anika Therapeutics, Inc. | 46.19M |
| Savara, Inc. | 48.48M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 112.09M |
| Shareholders Equity (Quarterly) | 40.38M |
| Debt to Equity Ratio | 0.2528 |
| Current Ratio | 0.7265 |
| Net Debt Paydown Yield | -1.86% |